Sun Pharmaceutical Industries has launched its innovative drug Ilumya in India. This medication treats moderate-to-severe plaque psoriasis....

Sun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This nov...

The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs ...

Shares of Sun Pharma closed 0.45 per cent down at Rs 401 on BSE.

China Medical System will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, t...

The stock rose 2.28 per cent to hit a high of Rs 657 on the BSE.

Last year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.

The drug which will be sold under the brand name Ilumya is expected to treat adults for moderate to severe plaque psoriasis, an autoimmune ...

The novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the con...

Sun Pharma said the approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential.

The FDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March ...

The filing includes efficacy and safety data from the pivotal Phase III clinical trials that included over 1,800 patients across more than ...

Tildrakizumab is a monoclonal antibody designed to control the pathogenic cells responsible for the inflammatory process of psoriasis with ...

In return, the Indian company will receive an initial upfront payment of $50 million and be eligible for development and regulatory milesto...

Stock of the pharma firm settled with a gain of 1.63 per cent at Rs 805.20 on the BSE. During the day, it climbed 2.78 per cent to Rs 814.4...

Tildrakizumab is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment.

Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck.